Last-Resort drug made available for stubborn melanoma patients
NCT ID NCT06063746
First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 23 times
Summary
This program offers compassionate access to vidutolimod for people with refractory melanoma, a type of skin cancer that has not responded to standard treatments. The goal is to provide a potential treatment option when no others are available. The study is no longer enrolling participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.